PMVP Company Profile and Key Details

PMVP has shown weak momentum, losing -7.69% over the past week and -22.86% over the past quarter, though year-to-date performance is down -13.6%. Short-term trend indicators are bullishly aligned (SMA20 25.57%, SMA50 19.17%, SMA200 9.35%). The stock’s 14-day RSI is 70.02 (overbought), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.54% below its high and over 69.14% above its low. Average 10-day trading volume of 246.55 thousand shares is below the 3-month average of 331.67 thousand, indicating normal recent market interest.

PMV Pharmaceuticals, Inc. generated EPS of -$1.58 over the past year. Five-year average earnings growth is -14.06%. Wall Street analysts project EPS growth of 3.53% annually over the next five years. The latest quarter delivered EPS of -$0.34. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$5.79. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 350.45% upside. The low target suggests 350.45% downside. The mean target is $5.00. This offers 350.45% upside. PMV Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -17.07%. The prior quarter beat by -15.0%. Over the last six quarters, Apple has recorded several small beats. These include 18.42% in March 03, 2025.

PMV Pharmaceuticals, Inc. has 53.33 million shares outstanding. The public float is 43.14 million shares, elevated short interest at 4.70% of float. This equals 2.42 million shares. The short ratio is 6.69 days. Institutional investors hold 70.1% of the float. Insiders own 3.35%. ORBIMED ADVISORS LLC holds 4.98 million shares, Schroeder Thilo has 1.10 million shares and Euclidean Capital LLC has 665.70 thousand shares.

PMV Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.71. This means the shares are trading above this model’s fair value.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) closed at $1.11 USD, losing -$0.02 (-1.77%) from the previous close of $1.13. The stock is currently mid-range between its 52-week high and low $1.02 and $1.88. With a market capitalization of about $59.20 million, PMV Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.33). Key stats such as the average daily volume over the past year has been around 339.10 thousand shares, volume is running light vs its 52-week average. Headquartered in Princeton, NJ, PMV Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David H. Mack, the company employs approximately 54 people and listed since September 25, 2020. PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) shares are down -13.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows PMV Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.75. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $23.78, suggesting 2042.34% upside. Our AI forecast model points to short-term weakness (-9.01% over two weeks), a medium-term fall (-39.64% over three months), and a longer-term gain (65.77% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PMV Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.01%, with price expected at $1.01 by August 13, 2026, within a range of $0.95 to $1.08 3-Month Outlook: Projected fall of -39.64%, reaching $0.67 by October 28, 2026, with a range of $0.61 to $0.72. 1-Year Outlook: Projected gain of 65.77%, with price at $1.84 by July 30, 2027, within a range of $0.00 to $0.42.

PMV Pharmaceuticals, Inc. trades at a P/E ratio of -0.75, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.68 suggesting the stock is closer to book value. The P/FCF stands at -0.8, also above market averages.